5 Trends in Biotech Dealmaking to Watch in 2021

BioPharma Dive

"Biopharma dealmakers had tempered their excitement heading into last year. After 2019 brought an unprecedented amount of activity, the odds of having another record-breaking stretch – especially so soon – looked slim. They also felt that with the upcoming US presidential election and its potential impact on drug policy, some companies would take a wait-and-see approach to deals."

Read the article

Related Contacts
Barbara Borden Partner San Diego
Marya Postner Partner Palo Alto